Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

211 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial.
Morita A, Strober B, Burden AD, Choon SE, Anadkat MJ, Marrakchi S, Tsai TF, Gordon KB, Thaçi D, Zheng M, Hu N, Haeufel T, Thoma C, Lebwohl MG. Morita A, et al. Among authors: lebwohl mg. Lancet. 2023 Oct 28;402(10412):1541-1551. doi: 10.1016/S0140-6736(23)01378-8. Epub 2023 Sep 19. Lancet. 2023. PMID: 37738999 Clinical Trial.
Phase 2 Trial of Difelikefalin in Notalgia Paresthetica.
Kim BS, Bissonnette R, Nograles K, Munera C, Shah N, Jebara A, Cirulli J, Goncalves J, Lebwohl M; KOMFORT Trial Investigators. Kim BS, et al. N Engl J Med. 2023 Feb 9;388(6):511-517. doi: 10.1056/NEJMoa2210699. N Engl J Med. 2023. PMID: 36780675 Clinical Trial.
Psychometric validation of the generalized pustular psoriasis physician global assessment (GPPGA) and generalized pustular psoriasis area and severity index (GPPASI).
Burden AD, Bissonnette R, Lebwohl MG, Gloede T, Anatchkova M, Budhiarso I, Hu N, Thoma C, Skalicky AM, Bachelez H. Burden AD, et al. Among authors: lebwohl mg. J Eur Acad Dermatol Venereol. 2023 Jul;37(7):1327-1335. doi: 10.1111/jdv.18999. Epub 2023 Mar 18. J Eur Acad Dermatol Venereol. 2023. PMID: 36854864 Free article.
The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score: online assessment and validation study of a specific measure of GPP disease activity.
Burden AD, Bachelez H, Choon SE, Marrakchi S, Tsai TF, Turki H, Morita A, Lebwohl MG, Bissonnette R, Zheng M, Anadkat MJ, Navarini AA, Tang M, Thoma C, Duffin KC. Burden AD, et al. Among authors: lebwohl mg. Br J Dermatol. 2023 Jul 7;189(1):138-140. doi: 10.1093/bjd/ljad071. Br J Dermatol. 2023. PMID: 37075220 Free article. No abstract available.
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis.
Strober B, Coates LC, Lebwohl MG, Deodhar A, Leibowitz E, Rowland K, Kollmeier AP, Miller M, Wang Y, Li S, Chakravarty SD, Chan D, Shawi M, Yang YW, Thaҫi D, Rahman P. Strober B, et al. Among authors: lebwohl mg. Drug Saf. 2024 Jan;47(1):39-57. doi: 10.1007/s40264-023-01361-w. Epub 2023 Oct 31. Drug Saf. 2024. PMID: 37906417 Free PMC article. Clinical Trial.
Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study.
Papp KA, Lebwohl MG, Thaçi D, Jaworski J, Kwiek B, Trefler J, Dudek A, Szepietowski JC, Reznichenko N, Narbutt J, Baran W, Kolinek J, Daniluk S, Bartnicka-Maslowska K, Reich A, Andrashko Y, Kim S, Bae Y, Jeon D, Jung J, Lee H, Pyo T, Ko W. Papp KA, et al. Among authors: lebwohl mg. BioDrugs. 2024 Jan;38(1):121-131. doi: 10.1007/s40259-023-00630-5. Epub 2023 Nov 22. BioDrugs. 2024. PMID: 37991693 Free PMC article. Clinical Trial.
Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study.
Papp K, Warren RB, Green L, Reich K, Langley RG, Paul C, Asahina A, Johnson L, Arora V, Osuntokun O, Lebwohl M. Papp K, et al. Lancet Rheumatol. 2023 Sep;5(9):e542-e552. doi: 10.1016/S2665-9913(23)00120-0. Epub 2023 Aug 21. Lancet Rheumatol. 2023. PMID: 38251498 Clinical Trial.
Psychometric validation of the Psoriasis Symptom Scale, Functional Assessment of Chronic Illness Therapy-Fatigue and pain-Visual Analogue Scale in patients with generalized pustular psoriasis.
Burden AD, Bissonnette R, Anatchkova M, Budhiarso I, Skalicky AM, Liberato ACS, Hu N, Thoma C, Gloede T, Kohlmann T, Lebwohl MG. Burden AD, et al. Among authors: lebwohl mg. J Eur Acad Dermatol Venereol. 2024 Feb 9. doi: 10.1111/jdv.19830. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 38334243
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).
Strober B, Blauvelt A, Warren RB, Papp KA, Armstrong AW, Gordon KB, Morita A, Alexis AF, Lebwohl M, Foley P, Kisa RM, Colston E, Wang T, Banerjee S, Thaçi D. Strober B, et al. J Eur Acad Dermatol Venereol. 2024 Mar 7. doi: 10.1111/jdv.19925. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 38451052
211 results